Health-care companies rose after a strong launch for one potential blockbuster. The pill formulation of Danish drug maker Novo Nordisk's Wegovy weight-control medication garnered almost as many ...
On Thursday, Eli Lilly and Co. (NYSE: LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide ...
Another frontier of GLP-1 therapy could be opening up. Clinical trial data out today finds that tirzepatide (the active ingredient in the GLP-1 weight loss drug Zepbound) can be an effective add-on ...
Jan 8 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis ...
Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake Jan ...
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...
Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater improvement in tender and swollen joints compared to those on Taltz alone, a new ...
As evidence of tirzepatide’s efficacy mounts across a range of cardiometabolic conditions, Eli Lilly has shown that taking the incretin medicine alongside another of its drugs, Taltz, could lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results